Anti-CD19 antibody [A3-B1] (FITC) (ab91155)

Overview

  • Product nameAnti-CD19 antibody [A3-B1] (FITC)
    See all CD19 primary antibodies
  • Description
    Mouse monoclonal [A3-B1] to CD19 (FITC)
  • ConjugationFITC. Ex: 493nm, Em: 528nm
  • Specificityab91155 is B lineage-specific and reacts with early B-cell precursors, pre-pre-B-cells, pre-B- cells, B-cells, intermediate B-cells, mature B-cells and some plasmacytoid cells. Plasma cells were found to be negative. This antibody does not react with other haemopoïetic cells. The antibody also reacts with pre-B-cell- lines, B lymphoblastoid cell-lines and Burkitt cell- lines, and with 50% of myeloma cell-lines. Virtually all non T-ALL, B-CLL and B-cell lymphomas were found to be positive, myeloma cells were found to be negative.
  • Tested applicationsSuitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Tissue/ cell preparation (Human)

  • Positive control
    • Human B cells

Properties

Applications

Our Abpromise guarantee covers the use of ab91155 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt
  • Application notesFlow Cyt: Use 20µl per test.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionAssembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
    • Involvement in diseaseDefects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    • Sequence similaritiesContains 2 Ig-like C2-type (immunoglobulin-like) domains.
    • Post-translational
      modifications
      Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Antibody deficiency due to defect in CD19, included antibody
      • AW495831 antibody
      • B lymphocyte antigen CD19 antibody
      • B lymphocyte surface antigen B4 antibody
      • B-lymphocyte antigen CD19 antibody
      • B-lymphocyte surface antigen B4 antibody
      • B4 antibody
      • CD19 antibody
      • CD19 antigen antibody
      • CD19 molecule antibody
      • Cd19 protein antibody
      • CD19_HUMAN antibody
      • CVID3 antibody
      • Differentiation antigen CD19 antibody
      • Leu 12 antibody
      • Leu-12 antibody
      • Leu12 antibody
      • MGC109570 antibody
      • MGC12802 antibody
      • T-cell surface antigen Leu-12 antibody
      see all

    Anti-CD19 antibody [A3-B1] (FITC) images

    • Human peripheral blood was labelled with ab91155 and analysed by flow cytometry.

    References for Anti-CD19 antibody [A3-B1] (FITC) (ab91155)

    ab91155 has not yet been referenced specifically in any publications.

    Product Wall

    Abcam has not validated the combination of species/application used in this Abreview.
    Application Flow Cytometry
    Sample Monkey Cell (cryopreserved PBMC)
    Specification cryopreserved PBMC
    Preparation Cell harvesting/tissue preparation method: cells were thawed and washed in RPMI with 10% FCS plus Pen/Strep. Cells were counted using Trypan blue. Cells were transferred into FACS tubes and washed with DPBS. Antibodies were added and cells were stained for 30 min in the dark at RT. As positive control human PBMC were included.
    Sample buffer: DPBS during staining, DPBS plus 2% Formaldehyde
    Fixation Formaldehyde
    Permeabilization No
    Gating Strategy Cells were gated on Lymphocytes (SSC/FSC) followed by CD3/CD14 negative gating followed by CD19 positive, Isotype or CD20 as alternative control
    Username

    Abcam user community

    Verified customer

    Submitted Jan 06 2011

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"